About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.
XL ERBB2 (HER2/NEU) amp
- Order Number
- Package Size
- 100 µl (10 Tests)
XL ERBB2 (HER2/NEU) amp consists of an orange-labeled probe hybridizing to the ERBB2 (HER2/NEU) gene region at 17q12 and a green-labeled probe hybridizing to the centromere of chromosome 17.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
Amplification or over-expression of the ERBB2 (HER2/NEU) gene occurs in approximately 15-30% of breast cancers. It is strongly associated with increased disease recurrence and a poor prognosis. Over-expression is also known to occur in ovarian, stomach, and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.
ERBB2, located on the long arm of human chromosome 17 (17q12), is a member of the epidermal growth factor receptor (EGFR/ErbB) family which is composed of four plasma membrane-bound receptor tyrosine kinases. Signaling through the ErbB family of receptors promotes cell proliferation and opposes apoptosis.
ERBB2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin®).
- Solid Tumors (Solid Tumors)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
Two green (2G), one orange (1O), and orange signal clusters, indicating amplification of ERBB2 (homogenous staining region = HSR).
Aberrant Cell (typical results): Two green (2G) and multiple copies of orange signals, indicating amplification of ERBB2 (double minutes = dm).
- Isola et al (1999) Clin Cancer Res 5:4140-4145
- Blancato et al (2004) Br J Cancer 90:1612-1619
- Singhi et al (2012) Mod Pathol 25:378-387